Kuros Biosciences AG
/ Key word(s): Miscellaneous
Schlieren (Zurich), Switzerland, 23 November, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the completion of enrollment in the randomized stage of the STRUCTURE trial, which is investigating the safety and efficacy of Fibrin-PTH (KUR-113) in transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease (DDD). No drug-related SAEs were reported in the first stage of the Phase 2 randomized, dose-finding, multi-center study. The STRUCTURE trial is being conducted under an open Investigational New Drug (IND) program for spinal fusion, which was filed with the U.S. Food and Drug Administration (FDA) in 2020. STRUCTURE will enroll 50 patients with DDD requiring single-level interbody fusion with concomitant posterolateral fusion (PLF). In the first stage of the trial, 30 patients were randomized into two arms, the first receiving Fibrin-PTH and the second receiving local autograft, which serves as control. Fibrin-PTH or local autograft were applied in and around FDA-cleared polyether-ether-ketone (PEEK) cages, respectively. Enrollment is underway for the remaining 20 patients for the second, non-randomized part of the trial, in which all subjects will receive Fibrin-PTH at a higher concentration. The primary endpoint of the trial is radiographic interbody fusion using CT scans at 12 months, as determined by an independent radiology expert panel. Joost de Bruijn, Chief Executive Officer of Kuros, said: "We are very pleased with the progress we are making in this investigational trial, which is the first time a drug-biologic combination product candidate is being tested as a bone graft for the treatment of DDD in a controlled clinical setting. Fibrin-PTH has the potential to transform the way spinal fusions are performed and, as such, we see a substantial commercial opportunity around this product candidate. We are pressing ahead with the next stage of this trial and are looking forward to full enrollment of the study and primary endpoint read out of the randomized part of the study due next year." For further information, please contact:
About Fibrin-PTH (KUR-113) About Spinal Fusion About Kuros Biosciences Forward Looking Statements 1. Data on file
End of Media Release |
Language: | English |
Company: | Kuros Biosciences AG |
Wagistrasse 25 | |
8952 Schlieren | |
Switzerland | |
Phone: | +41 44 733 4747 |
Fax: | +41 44 733 4740 |
E-mail: | info@kurosbio.com |
Internet: | www.kurosbio.com |
ISIN: | CH0325814116 |
Valor: | 32581411 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1494157 |
End of News | EQS News Service |
|
1494157 23.11.2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.